Screener
Viking Therapeutics VKTX Total Current Assets
Total Current Assets at other companies
Other financials
Where this comes from
Reported directly by Viking Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AssetsCurrent.
The source filing: Viking Therapeutics’s 10-Q, filed April 30, 2026.
- Filed
- Apr 29, 2026, 9:50 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-193315
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Short-term investments – available-for-sale | 484,848 | 539,929 |
| Prepaid clinical trial and preclinical study costs | 4,021 | 8,053 |
| Prepaid expenses and other current assets | 1,224 | 1,806 |
| Total current assets | 608,209 | 715,598 |
| Right-of-use assets | — | 85 |
| Deposits | 33 | 46 |
| Total assets | $608,242 | $715,729 |
| Liabilities and stockholders’ equity |
Item 1. Financial Statements
FAQ
- What is Viking Therapeutics's total current assets?
- Viking Therapeutics (VKTX) reported total current assets of $608.21M in Q1 2026.
- How has Viking Therapeutics's total current assets changed year-over-year?
- Viking Therapeutics's total current assets decreased by 29.8% year-over-year, from $866.02M to $608.21M.
- What is the long-term trend for Viking Therapeutics's total current assets?
- Over 5 years (2020 to 2025), Viking Therapeutics's total current assets has grown at a 22.8% compound annual growth rate (CAGR), from $256.1M to $715.6M.
- What does total current assets mean?
- The sum of all assets expected to be converted to cash or consumed within one year — cash, receivables, inventory, and prepaid expenses.
Ask your AI about Viking Therapeutics's total current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude